Dataset from A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN SUBJECTS WITH NEWLY DIAGNOSED CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00006820
下载链接
链接失效反馈官方服务：
资源简介：
Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of
bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase
Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one
year.
创建时间：
2025-09-06
